Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:UNH

UnitedHealth Group Inc (UNH)

411.04
+2.52 (0.62%)
as of Jun 15, 2026, 8:00:00 pm Market Open.
287 watching
0
Investor Insights
star iconJun 14, 2026, 12:00 am

This summary was created by AI, based on 43 opinions in the last 12 months.

UnitedHealth Group Inc (UNH-N) has faced considerable challenges over the past year, reflected in its declining stock price and regulatory scrutiny. Experts note that while the company is fundamentally strong with significant vertical integration in the U.S. healthcare system, it has been impacted by rising medical costs, regulatory pressures, and changes in Medicare reimbursement rates. The new CEO’s leadership is viewed as a positive factor that could guide the company through its current difficulties, but many analysts express caution due to the speculative nature of recent issues and the stock's volatility. Some believe the downturn creates buying opportunities, suggesting that long-term growth may be achievable if operational concerns are resolved. Overall, the sentiment is mixed, with a few experts optimistic about potential recovery while others advise caution until more clarity emerges.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Cvs, CVS
BUY

Likes it, with the economy opening up and the company securing some price increases. Not a home run stock. You're looking at returns of 10-15% per annum.

DON'T BUY

He owns many healthcare names including UHN, but isn't excited about these names because they have lost momentum. Their CFO has warned of higher costs, which has lowered the bar a today. Earnings beat today, yes, but the bar is very low.

BUY

A core holding. It performed well, though down 8% this year. Revenue is up 13%, though costs up 16%. Their medical ratio is at 83% vs. 81% last year, but in line with the street. Shares are jumping today on earnings.

BUY

Shares are down 9% YTD, but is rallying 8% today on strong earnings. Has always liked this stalwart in healthcare.

TOP PICK

Massive insurance company with very strong business.
Mostly benefiting from secular growth.
16% compounding rate in earnings. 
Current share price presenting great opportunity to buy.
Excellent long term hold.

HOLD

Down 7% today after UNH warned of higher costs ahead. The sell-off is an over-reaction. Of course, surgeries cost more because hospitals are supply-constrained so that slows growth. Also, insurers can reprice each year, raising prices. This will work itself out.

DON'T BUY

Trading way up at its FMV, and usually that's it for the stock. Not much more upside. Buy CNC instead.

PAST TOP PICK
(A Top Pick Feb 03/22, Up 2%)

It is a defensive stock that is executing very well as a large health insurance company with its own physician networks and clinics. It administers Medicare and Medicaid and has a clear runway for double digit growth. Yield is 1.3%

BUY

His preference in the space. It's insulated from retail exposure, which is impacted with more prescriptions being filled online. Benefits from trend to value-based care, which pays for patient outcomes rather than services provided.

BUY

He bought more yesterday. They're a perennial compounder. They will overcome the MLR (medical loss ratio), a concern. Management is almost flawless in reporting quarters and guiding. They will continue to grow.

BUY

Likes it. It's a compounder. Low unemployment is a catalyst for health. Medicare has been strong

BUY

Falling after earnings, though beat revenues and EPS and raised guidance. Are the cream of the crop in healthcare services. The fall comes from the lighter-than-expected guide, and they had a nice ride in recent weeks.

BUY ON WEAKNESS

They rallied into today's earnings. Though client acquisition has stagnated, their crossover business has grown revenues. He welcomes today's weakness, so he can add shares.

TOP PICK

Insurance for employers and individuals in the USA.
Overhang on the stock fading.
Has owned shares for a long time.
Believes prospects for business excellent.

BUY

The most consistent beat-and-raise company on the Dow. Add shares ahead of their Friday report.

Showing 106 to 120 of 285 entries